Irinotecan Arrow (Irinotecan Hydrochloride Trihydrate)

Irinotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. The drug stabilizes the enzyme‑DNA complex, preventing DNA strand re‑ligation, leading to DNA breaks that trigger cancer cell death.

The dose of Irinotecan Arrow is individualized by the prescribing oncologist based on factors such as body surface area, disease stage, and patient tolerance. Specific dosing regimens are determined by the treating physician and should not be self‑adjusted.

Safety of Irinotecan Arrow in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit outweighs the potential risk, and this decision should be made by a qualified healthcare professional.

To order Irinotecan Arrow, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to Irinotecan in colorectal cancer is the topoisomerase I inhibitor topotecan, though topotecan is less commonly used for this indication. Compared with oxaliplatin‑based regimens, Irinotecan offers a different toxicity profile, with more pronounced gastrointestinal and hematologic effects, while oxaliplatin is associated with neuropathy.

Irinotecan Arrow should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Before administration, allow the product to reach room temperature if required, and follow aseptic techniques to maintain sterility.

Irinotecan Arrow is administered intravenously by a qualified healthcare professional. It is typically infused over a set period, often 30 to 90 minutes, depending on the prescribed regimen and patient tolerance. Infusion should be performed in a setting equipped to manage potential acute reactions.

The most serious risks include febrile neutropenia, severe diarrhea that can lead to dehydration or colitis, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, gastrointestinal distress, and any allergic symptoms, and report them immediately to their care team.

Irinotecan Arrow should not be used in patients with known hypersensitivity to Irinotecan or any component of the formulation, in those with severe bone‑marrow suppression, or in individuals with uncontrolled infections. Caution is also advised for patients with significant hepatic impairment or pre‑existing gastrointestinal disorders.